Page last updated: 2024-10-24

positive regulation of adenylate cyclase-inhibiting dopamine receptor signaling pathway

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate or extent of adenylate cyclase-inhibiting dopamine receptor signaling pathway. [GO_REF:0000058, GOC:kmv, GOC:TermGenie, PMID:26554819]

The positive regulation of adenylate cyclase-inhibiting dopamine receptor signaling pathway is a complex process involving a series of molecular events that ultimately lead to an increase in the activity of the adenylate cyclase-inhibiting dopamine receptor. This receptor, also known as the D2 dopamine receptor, is a G protein-coupled receptor (GPCR) that is primarily responsible for mediating the inhibitory effects of dopamine in the brain.

The pathway begins with the binding of dopamine to the D2 receptor. This interaction triggers a conformational change in the receptor, which then activates a heterotrimeric G protein. The G protein consists of three subunits: alpha (α), beta (β), and gamma (γ). Upon activation, the α subunit dissociates from the βγ subunits and binds to adenylate cyclase, an enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP).

In this pathway, however, the D2 receptor is an inhibitory receptor. Therefore, activation of the G protein leads to the inhibition of adenylate cyclase, resulting in a decrease in cAMP production. This reduction in cAMP levels ultimately leads to the inhibition of downstream signaling pathways, such as the protein kinase A (PKA) pathway.

The positive regulation of this pathway involves processes that enhance the activity of the D2 receptor or its associated signaling molecules. These processes can include:

* **Increased dopamine synthesis and release:** A higher concentration of dopamine in the synapse will lead to greater activation of the D2 receptor.
* **Increased receptor expression:** An increase in the number of D2 receptors on the cell surface will enhance the overall signaling response.
* **Phosphorylation of the receptor:** Phosphorylation of the D2 receptor by specific kinases can modulate its activity and enhance signaling.
* **Activation of downstream signaling molecules:** Factors that stimulate the activity of the G protein or other components of the signaling pathway can indirectly enhance the inhibitory effects of the D2 receptor.

The positive regulation of this pathway is crucial for maintaining proper dopaminergic signaling in the brain. It plays a role in various neurological processes, including motor control, reward, and motivation. Dysregulation of this pathway has been implicated in several neurological disorders, including Parkinson's disease, schizophrenia, and addiction.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Protein arginine N-methyltransferase 5A protein arginine N-methyltransferase 5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O14744]Homo sapiens (human)

Compounds (12)

CompoundDefinitionClassesRoles
pentamidinepentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.

Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
aromatic ether;
carboxamidine;
diether
anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
s-adenosylmethionineacylcarnitine: structure in first source

S-adenosyl-L-methioninate : A sulfonium betaine that is a conjugate base of S-adenosyl-L-methionine obtained by the deprotonation of the carboxy group.
sulfonium betainehuman metabolite
hexamidinehexamidine : A polyether that is the bis(4-guanidinophenyl) ether of hexane-1,6-diol.aromatic ether;
guanidines;
polyether
antimicrobial agent;
antiseptic drug
sinefunginadenosines;
non-proteinogenic alpha-amino acid
antifungal agent;
antimicrobial agent
furamidinefuramidine: RN given refers to parent cpd; WR 199385 refers to di-HCl; pafuramidine is a prodrug of this
s-adenosylhomocysteineS-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine.

S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions.
adenosines;
amino acid zwitterion;
homocysteine derivative;
homocysteines;
organic sulfide
cofactor;
EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor;
EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor;
epitope;
fundamental metabolite
5'-methylthioadenosine5'-methylthioadenosine: structure

5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group.
thioadenosinealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
stilbamidinestilbamidine: RN given refers to parent cpd
epz004777N-glycosyl compound
gsk343GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM).

GSK343: an EZH2 methyltransferase inhibitor
aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide
antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source
gsk3235025GSK3235025: an inhibitor of protein arginine methyltransferase-5 (PRMT5); structure in first source